The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: Enhancement of growth inhibition via inhibition of mammalian target of rapamcycin signaling

Molecular Cancer Therapeutics

Volumn 5, Issue 10, 2006, Pages 2522-2530

  Ikezoe, Takayuki ^a   Nishioka, Chie ^a   Tasaka, Taizo ^b   Yang, Yang ^a   Komatsu, Naoki ^a   Togitani, Kazuto ^a   Koeffler, H Phillip ^c   Taguchi, Hirokuni ^a  

^a KOCHI UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; FLT3 LIGAND; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P70; PROTEIN TYROSINE KINASE INHIBITOR; S6 KINASE; STEM CELL FACTOR; SUNITINIB; THYMIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL ISOLATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; EOSINOPHILIC LEUKEMIA; FEMALE; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T CELL LYMPHOMA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; HEMATOLOGIC NEOPLASMS; HUMANS; INDOLES; LEUKEMIA; MUTATION; PHOSPHOPROTEINS; PROTEIN KINASES; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 33750483896     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0071     Document Type: Article

References (32)

1. Broudy VC. Stem cell factor and hematopoiesis. Blood 1997;90: 1345-64.
2. Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000;19: 624-31.
3. Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000;96:3907-14.
4. Abu-Duhier FM, Goodeve AC, Wilson GA, et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 2000;111:190-5.
5. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML)* adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752-9.
6. Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic significance of FIt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001;97:89-94.
7. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326-35.
8. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97:2434-9.
9. Beghini A, Peterlongo P, Ripamonti CB, et al. c-Kit mutations in core binding factor leukemias. Blood 2000;95:726-7.
10. Beghini A, Larizza L, Cairoli R, Morra E. c-Kit activating mutations and mast cell proliferation in human leukemia. Blood 1998;92:701-2.
11. Beghini A, Magnani I, Ripamonti CB, Larizza L. Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia. Hematol J 2002;3:157-63.
12. Cools J, Quentmeier H, Huntly BJ, et al. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2004; 103:2802-5.
13. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80.
14. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy an safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
15. Bjornsti MA, Houghton PJ. Lost in translation: dysregulation of capdependent translation and cancer. Cancer Cell 2004;5:519-23.
16. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-45.
17. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004;91:1420-4.
18. Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1 H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003;46:1116-9.
19. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
20. Ikezoe T, Yang Y, Bandobashi K, Taguchi T, Koeffler HP, Taguchi H. Effect of SU11248, a class III receptor tyrosine kinase inhibitor, on GIST-T1 cells and enhancement of growth inhibition mediated by the inhibitors of PI3-K/Akt/mTOR signaling. AACR-NCI-EORTC International Conference 2005, Philadelphia, USA. (Abstr. B46).
21. Atkins M, Jones CA, Kirkpatrick P. Sunitinib maleate. Nat Rev Drug Discov 2006;5:279-80.
22. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-605.
23. Yee KW, Schittenhelm M, O'Farrell AM, et al. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood 2004; 104:4202-9.
24. Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005; 105: 986-93.
25. Asou H, Tashiro S, Hamamoto K, Otsuji A, Kite K, Kamada N. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 1991;77:2031-6.
26. Miyagi T, Ohyashiki J, Yamato K, Koeffler HP, Miyoshi I. Phenotypic and molecular analysis of Ph1-chromosome-positive acute lymphoblastic leukemia cell lines. Int J Cancer 1993;53:457-62.
27. Kubonishi I, Miyoshi I. Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis. Int J Cell Cloning 1983;1:105-17.
28. Ikezoe T, Yang Y, Bandobashi K, et al. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-κ B signal pathways. Mol Cancer Ther 2005;578-86.
29. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
30. Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST. Bcr-AbI kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 2003;63:5716-22.
31. Mohi MG, Boulton C, Gu TL, et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A 2004;101:3130-5.
32. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003;102:972-80.